Timing of 3rd-Trimester Maternal Tdap Immunization Associated With Levels of Whooping Cough Antibodies in Newborns



Media advisory: To contact corresponding author C. Mary Healy, M.D., email Jeannette Jimenez at Jeannette.Jimenez@bcm.edu. The full study is available on the For The Media website.

Want to embed a link to this study in your story? Link will be live at the embargo time: http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2018.14298


Bottom Line: Risk of whooping cough (pertussis) is highest in infants too young to have completed their primary immunization series (6 months old or younger) and they are at highest risk of developing life-threatening complications. Immunizing pregnant women with the tetanus, diphtheria and acellular pertussis (Tdap) vaccine can create enough maternal antibodies to protect infants, but the best time to immunize mothers to maximize concentrations of neonatal pertussis toxin antibodies is unknown. This observational study included 626 pregnancies and compared pertussis antibody concentrations in umbilical cord blood among newborns whose mothers received Tdap immunization in the third trimester, as is recommended by the U.S. Centers for Disease Control and Prevention, with those whose mothers didn’t receive the Tdap vaccine during pregnancy. Maternal immunization with the Tdap vaccine during the third trimester of pregnancy was associated with higher concentrations of pertussis antibodies in infants at birth, with immunization early in the third trimester associated with the highest concentrations of antibodies. Definitive antibody concentration levels for immunity from whooping cough for infants are unknown. The study design doesn’t allow for cause-and-effect interpretations of the findings.

Authors: C. Mary Healy, M.D., Baylor College of Medicine, Houston, and coauthors

Related Material

Previously published by JAMA: Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants

To Learn More: The full study is available on the For The Media website.


Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.